Pulse Biosciences, Inc. (Nasdaq: PLSE) has announced the appointment of Paul A. LaViolette to its Board of Directors. Mr. LaViolette will serve as Co-Chairman alongside Robert W. Duggan, bringing his expertise as an independent director to the role. Pulse Biosciences is known for its innovative Nanosecond Pulsed Field Ablation™ (nsPFA™) technology.
Pulse Biosciences’ Co-Chairman Robert W. Duggan expressed enthusiasm about Paul LaViolette joining the Board, highlighting his extensive experience and impact in medical technology. Duggan emphasized LaViolette’s expertise in scaling major cardiology franchises and driving innovative technology adoption, which will be valuable to Pulse Biosciences.
Paul LaViolette, Managing Partner at SV Health Investors, brings a wealth of experience from his tenure at Boston Scientific and various leadership roles at CR Bard and Kendall (Medtronic). His current roles include directorships at Edwards Lifesciences and the Innovation Advisory Board at Mass General Brigham.
LaViolette expressed honor at joining Pulse Biosciences, praising the Company’s unique technology and its potential to advance clinical care. He looks forward to contributing to the development of transformative treatments for unmet patient needs.
Pulse Biosciences, headquartered in Miami with an office in Hayward, specializes in bioelectric medicine using its proprietary CellFX® nsPFA™ technology.
